In the Journals

Pazopanib effective after progression in metastatic clear-cell RCC

Pazopanib appeared effective in patients with metastatic clear-cell renal cell carcinoma who had progressive disease after targeted therapy, according to results of a retrospective study published in the European Journal of Cancer.

Marc Matrana, MD, lead study author and co-director of the Clinical Oncology Research Program at the Ochsner Medical Center, New Orleans, and colleagues reviewed data from 93 consecutive patients with metastatic clear-cell renal cell carcinoma who had undergone a median two prior targeted therapies (range, 1-5). All patients received pazopanib (Votrient, GlaxoSmithKline) from November 2009 through 2011.

 

Marc Matrana

A blinded radiologist used RECIST criteria to assess tumor response.

Researchers reported 68 events, defined as death or progressive disease.

Thirteen of the 85 (15%) evaluable patients demonstrated partial response. Researchers reported median PFS of 6.5 months (95% CI, 4.5-9.7) and median OS of 18.1 months (95% CI, 10.26-NA).

Researchers reported manageable mild-to-moderate toxicities.

The most common adverse events were fatigue (44%), elevated transaminase levels (35%), diarrhea (30%), hypothyroidism (18%), nausea or vomiting (17%), anorexia (14%) and hypertension exacerbation (14%). Ninety-one percent of adverse events were grade 1-2.

The researchers noted 11 patients (12%) discontinued the therapy due to adverse events, but there were no deaths related to treatment.

“Our findings suggest that pazopanib is efficacious and well tolerated in the salvage setting after failure of other targeted therapies, including other VEGF-targeted tyrosine kinase inhibitors,” Matrana told HemOnc Today. “This supports the use of pazopanib in a real world setting even in patients with relatively poor performance status and multiple co-morbidities.”

Disclosures: The researchers report funding from GlaxoSmithKline.

Pazopanib appeared effective in patients with metastatic clear-cell renal cell carcinoma who had progressive disease after targeted therapy, according to results of a retrospective study published in the European Journal of Cancer.

Marc Matrana, MD, lead study author and co-director of the Clinical Oncology Research Program at the Ochsner Medical Center, New Orleans, and colleagues reviewed data from 93 consecutive patients with metastatic clear-cell renal cell carcinoma who had undergone a median two prior targeted therapies (range, 1-5). All patients received pazopanib (Votrient, GlaxoSmithKline) from November 2009 through 2011.

 

Marc Matrana

A blinded radiologist used RECIST criteria to assess tumor response.

Researchers reported 68 events, defined as death or progressive disease.

Thirteen of the 85 (15%) evaluable patients demonstrated partial response. Researchers reported median PFS of 6.5 months (95% CI, 4.5-9.7) and median OS of 18.1 months (95% CI, 10.26-NA).

Researchers reported manageable mild-to-moderate toxicities.

The most common adverse events were fatigue (44%), elevated transaminase levels (35%), diarrhea (30%), hypothyroidism (18%), nausea or vomiting (17%), anorexia (14%) and hypertension exacerbation (14%). Ninety-one percent of adverse events were grade 1-2.

The researchers noted 11 patients (12%) discontinued the therapy due to adverse events, but there were no deaths related to treatment.

“Our findings suggest that pazopanib is efficacious and well tolerated in the salvage setting after failure of other targeted therapies, including other VEGF-targeted tyrosine kinase inhibitors,” Matrana told HemOnc Today. “This supports the use of pazopanib in a real world setting even in patients with relatively poor performance status and multiple co-morbidities.”

Disclosures: The researchers report funding from GlaxoSmithKline.